Next steps will be to conduct efficacy studies to show whether
reducing mutant huntingtin can slow down disease progression.
In an announcement likely to stand as one of the biggest breakthroughs in Huntington's disease since the discovery of the HD gene in 1993, Ionis and Roche today announced that the first human trial of a huntingtin - lowering drug, IONIS - HTTRx, demonstrates that
it reduces mutant huntingtin in the nervous system, and is safe and well - tolerated.
Not exact matches
University of California, Irvine neurobiologists Leslie Thompson and Joseph Ochaba with the Departments of Neurobiology & Behavior and Psychiatry & Human Behavior and their colleagues from UCI and from Children's Hospital of Philadelphia have shown that
reducing the aberrant accumulation of a particular form of the
mutant Huntingtin protein corresponds to improvement in symptoms and neuroinflammation in HD mice.
2015 will see the start of the first human clinical trial of a gene silencing or
huntingtin - lowering drug, which specifically aims to
reduce production of
mutant huntingtin in the brains of HD patients.
The phase 1 / 2a study of IONIS - HTTRx was recently completed and showed the therapy to be safe and well - tolerated but also showed it's ability to
reduce the level of
mutant huntingtin in a dose dependent manner in Huntington's Disease patients.
Activity of the
mutant huntingtin gene was
reduced by around 50 % in the brain near the injection site.
The appearance of blobs of
mutant huntingtin protein was
reduced by about 40 %, too.
We hope this will allow WAVE to actually measure what they're trying to do, which is to
reduce the levels of the
mutant huntingtin protein in the brain.
Some of these approaches to attack
mutant huntingtin also
reduce levels of the normal protein, including the Ionis
huntingtin - lowering drug.